Table 1 Demographics of study population
No. patients | 12 | |
|---|---|---|
Age at transplant, yr ± SD (range) | 52.88 ± 4.70 (44–60) | |
Time posttransplant, yr ± SD (range) | 7.70 ± 6.31 (1–21) | |
Age at study, yr ± SD (range) | 60.58 ± 7.10 (48–70) | |
Gender (M:F) | 10:2 | |
Immunosuppression at study | Â | |
| Â | Tacrolimus | 7/12 |
| Â | Cyclosporine | 2/12 |
| Â | mTor inhibitors | 3/12 |
ALT, U/L ± SD | 131.4 ± 117.2 | |
AST, U/L ± SD | 85.0 ± 52.6 | |
Total bilirubin, mg/dl ± SD | 1.79 ± 2.31 | |
HCV genotype (1/2/3; %) | 75/8/17 | |
IL28B genotype (CC/CT/TT; %) | 25/50/25 | |
HCV-RNA (log 10 IU/ml; mean ± SD) | 6.38 ± 0.58 | |